papillary thyroid carcinoma
Conditions
Interventions
Clinical tissue sample validation group:NA
Sponsors
Baotou Cancer Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1.Pathological diagnosis. After postoperative histopathological examination, it was diagnosed as papillary thyroid carcinoma (PTC), which meets the WHO classification criteria for thyroid tumors. Clear lymph node status: N0 group: No central lymph node metastasis (CLNM) was found in preoperative imaging evaluation (ultrasound/CT) and postoperative pathology. N1 group: Postoperative pathology confirmed the presence of central lymph node metastasis (CLNM >= 1). 2.Sample requirements. Sufficient fresh or frozen tissue samples can be obtained, including: Tumor tissue: tissue in the core area of the primary lesion (volume >= 50mg). Pericancerous tissue: Normal thyroid tissue located >= 1cm from the edge of the tumor (without visible tumor infiltration). Metastatic lymph node tissue (N1 group only): Pathological confirmed metastatic lymph node tissue (volume >= 50mg). 3.Complete clinical data. Having complete preoperative examination data (including ultrasound, fine needle aspiration cytology/DNA results, serum TSH, Tg levels). The postoperative pathological report should include key information such as tumor size, multifocal nature, capsule invasion, BRAF V600E mutation status, etc. 4.Patient status 70 >= Age >= 18 years old, gender not limited. Sign the informed consent form and voluntarily participate in the research.
Exclusion criteria
Exclusion criteria: 1.Merge with other malignant tumors. History of malignant tumors other than thyroid cancer (excluding superficial cancers such as basal cell carcinoma of the skin and cervical carcinoma in situ). 2.Previous treatment interference. Received radiation therapy, chemotherapy, targeted therapy, or immunotherapy before surgery. Has undergone thyroid surgery (such as partial thyroidectomy, radiofrequency ablation, etc.). 3.Sample quality issues. Tissue samples may undergo RNA/DNA degradation due to intraoperative fragmentation, improper fixation, or inadequate storage conditions (such as failure to freeze with liquid nitrogen in a timely manner). Pathological examination of adjacent tissues revealed tumor cell infiltration. 4.Serious complications or contraindications. Merge severe heart, liver, and kidney dysfunction (such as heart function grade III or above, ChildPugh grade C cirrhosis, eGFR<30 mL/min/1.73m ²). There is coagulation dysfunction or uncontrolled systemic infection, which affects surgical safety. 5.Other exclusion factors. Pregnant or lactating women. Unable to cooperate with follow-up due to mental illness or cognitive impairment. Not agreeing to participate in the research for various reasons.
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| The frequency and type of mutations at NSUN6 related sites in mitochondrial DNA, such as missense mutations and nonsense mutations; | — |
Primary
| Measure | Time frame |
|---|---|
| Relative mRNA expression levels of NSUN6 in tumors, adjacent tumors, and metastatic lymph nodes; | — |
Countries
China
Contacts
Public ContactHan Bo
Baotou Cancer Hospital
Outcome results
None listed